Research and Markets: PharmaPoint: HIV - Germany Drug Forecast and Market Analysis to 2022

Wed Mar 6, 2013 6:58am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130306:nBw065678a

DUBLIN--(Business Wire)--

Research and Markets

(http://www.researchandmarkets.com/research/v74dvx/pharmapoint_hiv) has
announced the addition of GlobalData's new report "PharmaPoint: HIV - Germany
Drug Forecast and Market Analysis to 2022" to their offering. 

GlobalData has released its new Country report, PharmaPoint: HIV - Germany Drug
Forecast and Market Analysis to 2022. Human Immunodeficiency Virus (HIV), the
causative agent of AIDS, has claimed millions of lives since its emergence.
However, the advent of antiretroviral therapy (ART) has transformed the face of
HIV/AIDS from a deadly disease to a manageable chronic condition for most
infected individuals. Antiretroviral treatment not only reduces the viral load
and reconstitutes immune function, but also decreases infection incidence rates
by limiting viral transmission. 

The treatment algorithm in HIV has characteristically involved multiple drug
regimens designed to tackle the virus on different levels. In the recent past,
simplified dosing regimens through the emergence of single tablet regimens
(STRs) or fixed dose combination (FDC) therapies have become increasingly
popular amongst physicians and patients alike by increasing clinical efficacy
thresholds and enabling patient compliance. 

Newer STRs are expected to be released and will replace Atripla as the market
leader during the forecast period. As a whole, the market share of the STRs will
be affected by key patent expiries, such as those of BMS' Sustiva, which is a
key component of Atripla. Combined with healthcare budget restrictions imposed
by the general financial situation in Europe, this might lead to a drastic drop
in Atripla sales and increase the barrier to entry for novel STRs. 

Scope 

- Overview of Germany including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive
landscape. 

- Detailed information on the key drugs in Germany including product
description, safety and efficacy profiles as well as a SWOT analysis. 

- Sales forecast for the top drugs in Germany from 2012-2022. 

- Analysis of the impact of key events as well the drivers and restraints
affecting Germany HIV market. 

For more information visit
http://www.researchandmarkets.com/research/v74dvx/pharmapoint_hiv

Source: GlobalData

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.